EXEL vs. VRTX

Last updated Apr 1, 2026

Compare and contrast key facts about Exelixis, Inc. (EXEL) and Vertex Pharmaceuticals Incorporated (VRTX).

Performance

EXEL vs. VRTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Exelixis, Inc. (EXEL) and Vertex Pharmaceuticals Incorporated (VRTX). The values are adjusted to include any dividend payments, if applicable.

EXEL vs. VRTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
EXEL Exelixis, Inc.	-2.14%	31.62%	38.81%	49.56%	-12.25%	-8.92%	13.90%	-10.42%	-35.30%	103.89%
VRTX Vertex Pharmaceuticals Incorporated	-1.50%	12.58%	-1.03%	40.90%	31.50%	-7.08%	7.94%	32.13%	10.58%	103.42%

Fundamentals

Market Cap EXEL : $12.09B VRTX : $114.36B
EPS EXEL : $2.76 VRTX : $15.35
PE Ratio EXEL : 15.52 VRTX : 29.09
PEG Ratio EXEL : 0.27 VRTX : 2.42
PS Ratio EXEL : 5.24 VRTX : 9.58
PB Ratio EXEL : 5.59 VRTX : 6.13
Total Revenue (TTM) EXEL : $2.32B VRTX : $12.00B
Gross Profit (TTM) EXEL : $2.24B VRTX : $10.35B
EBITDA (TTM) EXEL : $934.65M VRTX : $4.74B

Returns By Period

In the year-to-date period, EXEL achieves a -2.14% return, which is significantly lower than VRTX's -1.50% return. Over the past 10 years, EXEL has outperformed VRTX with an annualized return of 26.62%, while VRTX has yielded a comparatively lower 18.89% annualized return.

EXEL

• 1D: 2.24%
• 1M: -2.66%
• YTD: -2.14%
• 6M: 3.85%
• 1Y: 16.17%
• 3Y*: 30.25%
• 5Y*: 13.15%
• 10Y*: 26.62%

VRTX

• 1D: 0.76%
• 1M: -10.12%
• YTD: -1.50%
• 6M: 14.02%
• 1Y: -7.90%
• 3Y*: 12.33%
• 5Y*: 15.95%
• 10Y*: 18.89%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

EXEL vs. VRTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EXEL

EXEL Risk / Return Rank: 56
EXEL Sharpe Ratio Rank: 56
EXEL Sortino Ratio Rank: 52
EXEL Omega Ratio Rank: 54
EXEL Calmar Ratio Rank: 58
EXEL Martin Ratio Rank: 58

VRTX

VRTX Risk / Return Rank: 31
VRTX Sharpe Ratio Rank: 32
VRTX Sortino Ratio Rank: 29
VRTX Omega Ratio Rank: 29
VRTX Calmar Ratio Rank: 32
VRTX Martin Ratio Rank: 31

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EXEL vs. VRTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Exelixis, Inc. (EXEL) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	EXEL	VRTX	Difference
Sharpe ratio Return per unit of total volatility	0.37	-0.22	+0.59
Sortino ratio Return per unit of downside risk	0.83	-0.05	+0.88
Omega ratio Gain probability vs. loss probability	1.12	0.99	+0.13
Calmar ratio Return relative to maximum drawdown	0.67	-0.33	+1.00
Martin ratio Return relative to average drawdown	1.55	-0.65	+2.21
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

EXEL vs. VRTX - Sharpe Ratio Comparison

The current EXEL Sharpe Ratio is 0.37, which is higher than the VRTX Sharpe Ratio of -0.22. The chart below compares the historical Sharpe Ratios of EXEL and VRTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	EXEL	VRTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.37	-0.22	+0.59
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.36	0.56	-0.20
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.60	0.57	+0.03
Sharpe Ratio (All Time) Calculated using the full available price history	0.07	0.26	-0.19

Correlation

The correlation between EXEL and VRTX is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

EXEL vs. VRTX - Dividend Comparison

Neither EXEL nor VRTX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

EXEL vs. VRTX - Drawdown Comparison

The maximum EXEL drawdown since its inception was -97.38%, which is greater than VRTX's maximum drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for EXEL and VRTX.

Drawdown Indicators

	EXEL	VRTX	Difference
Max Drawdown Largest peak-to-trough decline	-97.38%	-91.77%	-5.61%
Max Drawdown (1Y) Largest decline over 1 year	-25.34%	-28.06%	+2.72%
Max Drawdown (5Y) Largest decline over 5 years	-41.47%	-29.07%	-12.40%
Max Drawdown (10Y) Largest decline over 10 years	-57.20%	-41.60%	-15.60%
Current Drawdown Current decline from peak	-12.91%	-13.59%	+0.68%
Average Drawdown Average peak-to-trough decline	-71.55%	-37.81%	-33.74%
Ulcer Index Depth and duration of drawdowns from previous peaks	10.85%	14.33%	-3.48%

Volatility

EXEL vs. VRTX - Volatility Comparison

The current volatility for Exelixis, Inc. (EXEL) is 6.86%, while Vertex Pharmaceuticals Incorporated (VRTX) has a volatility of 11.93%. This indicates that EXEL experiences smaller price fluctuations and is considered to be less risky than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	EXEL	VRTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.86%	11.93%	-5.07%
Volatility (6M) Calculated over the trailing 6-month period	26.58%	21.67%	+4.91%
Volatility (1Y) Calculated over the trailing 1-year period	43.76%	35.83%	+7.93%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	36.84%	28.77%	+8.07%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	44.88%	33.24%	+11.64%

Financials

EXEL vs. VRTX - Profitability Comparison

The chart below illustrates the profitability comparison between Exelixis, Inc. and Vertex Pharmaceuticals Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

EXEL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Exelixis, Inc. reported a gross profit of 572.18M and revenue of 598.66M. Therefore, the gross margin over that period was 95.6%.

VRTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Vertex Pharmaceuticals Incorporated reported a gross profit of 2.72B and revenue of 3.19B. Therefore, the gross margin over that period was 85.4%.

EXEL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Exelixis, Inc. reported an operating income of 235.22M and revenue of 598.66M, resulting in an operating margin of 39.3%.

VRTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Vertex Pharmaceuticals Incorporated reported an operating income of 1.26B and revenue of 3.19B, resulting in an operating margin of 39.6%.

EXEL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Exelixis, Inc. reported a net income of 244.53M and revenue of 598.66M, resulting in a net margin of 40.9%.

VRTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Vertex Pharmaceuticals Incorporated reported a net income of 1.19B and revenue of 3.19B, resulting in a net margin of 37.3%.